206 results about "Brain gliomas" patented technology

The invention belongs to the technical field of computer-aided diagnosis, and specifically relates to a brain glioma molecular marker nondestructive prediction method and a prediction system based on radiomics. The method comprises the following steps: adopting a three-dimensional magnetic resonance image automatic segmentation method based on a convolution neural network; registering a tumor obtained from segmentation to a standard brain atlas, and acquiring 116 position features of tumor distribution; getting 21 gray features, 15 shape features and 39 texture features through calculation; carrying out three-dimensional wavelet decomposition on the gray features and the texture features to get 480 wavelet features of eight sub-bands; acquiring 671 high-throughput features from the three-dimensional T2-Flair magnetic resonance image of each case; using a feature screening strategy combining p-value screening and a genetic algorithm to get 110 features highly associated with IDH1; and using a support vector machine and an AdaBoost classifier to get a classification of which the IDH1 prediction accuracy is 80%. As a novel method of radiomics, the method provides a nondestructive prediction scheme of important molecular markers for clinical diagnosis of gliomas.

The invention provides a human brain glioma cell line and an establishing method and application thereof. The human brain glioma cell line is preserved in China Center for Typical Culture Collection with an accession number of CCTCC No. C201115. The human brain glioma cell line is established by subjecting brain glioma cells originated from a clinic specimen to primary culture and subculture, can be directly used for in vitro drug screening or generation of human brain glioma in mammals and is used for establishing a human brain glioma animal model and screening candidate drugs used for treating human brain glioma. The human brain glioma cell line has stable properties, can realize stable multiple passages and maintain stable properties even after in vitro passage to the 50th generation; pathogenesis of human brain glioma, drug susceptibility, transitivity and other related characteristics can be analyzed in vitro and in vivo, so two correlated in-vitro and in-vivo anti-brain glioma drug screening platforms can be established, and novel experimental materials closer to clinic oncobiological characteristics are provided for research on human brain glioma.

The invention belongs to the technical field of image segmentation, and specifically relates to a 3D full-automatic glioma segmentation method combining a Volume of Interest and a GrowCut algorithm. The method first expands a Bounding box algorithm to 3D, utilizes the algorithm to extract a Volume of Interest (VOI) containing glioma, then utilizes a reflection symmetry algorithm to estimate the VOI and overcomes the defects of Bounding box when the glioma is detected to cross over a median sagittal plane, and finally marks pixel points in an image based on the accurate VOI, and thus a semi-automatic 2D GrowCut algorithm is optimized to a full-automatic 3D segmentation method. While accurately segmenting the glioma, the method is more rapid in theory and reality compared with the 2D segmentation algorithm of the same principle, and is better in convenience and feasibility compared with a manual segmentation method. As an image segmentation method, the 3D full-automatic glioma segmentation method provided by the invention can serve as a powerful auxiliary tool for clinical diagnosis of glioma.

The invention belongs to the field of biotechnology and medicine and relates to an application of miR-219, a new marker of human brain glioma. The fact that the expressions of miR-219 in the human brain glioma tissues and cells are obviously reduced is confirmed for the first time, and the facts that miR-219 can directly control Hh-Gli2 and Pdgfra signal paths during early development of the neural tube of embryo and occurrence of the brain glioma and can obviously suppress proliferation and infiltration of human glioma cells are confirmed. Further quantitative analysis of clinical brain glioma specimens at different levels shows that miR-219 can serve as the marker for detecting the brain glioma.

The invention relates to an application of anti-sense miRNA (Ribonucleic Acid)-210to the preparation of an anti-cancer drug, in particular to an application of anti-sense miRNA-210. The anti-sense miRNA-210 for preparing the anti-cancer drug belongs to the technical field of biomedical materials. In the application, a miRNA chip is adopted to research the expression situation of three examples of brain glioma miRAN, nine examples of brain glioma samples and four strains of brain glioma cells are verified by a chip result with Northern and q-PCR (Polymerase Chain Reaction) methods and the like, and a result proves that the anti-sense miRNA-210 can obviously lower the invasion capability of the brain glioma cell strains.

The invention relates to dibenzo iodonium salts represented by the following structural formula (I), and discloses a preparation method and an application thereof. In in-vitro experiments, the iodonium salts substantially inhibit the growths of cells of human-sourced pancreatic cancer, stomach cancer, colon cancer and other malignant tumors, and provide substantially killing effects against cells of ovarian cancer, lung cancer, liver cancer, leukemia, glioma, bone marrow cancer and other malignant tumors. In animal experiments, with the salts, the growths of human pancreatic cancer and colon cancer xenografts in nude mice can be substantially inhibited. The compounds can be used in developing novel antitumor medicines. (I) is shown below.

The invention discloses a dual-mode probe applicable to magnetic resonance imaging and near infrared imaging, wherein a gadolinium-doped manganese carbonate nanoparticle serves as a crystal core, and a silylating reagent, polyethylene glycol, near infrared dye and a target for targeting brain gliomas are combined on the surface of the crystal core. Furthermore, the invention discloses a preparation method of the gadolinium-doped manganese carbonate magnetic resonance imaging contrast agent, a modifying method of a fluorescent probe and application of the probe to targeting brain glioma imaging. The dual-mode probe disclosed by the invention is highly dispersed and stable in water, is applicable to dual-mode imaging of tumors and also can be applied to a drug carrier, cell tracing and gene transfection.

The invention especially relates to a radioactive C-MET-targeted affinity micromolecular compound and application thereof, belonging to the field of medical diagnosis and treatment. According to the invention, in-vivo tracking and imaging of diseases like tumors is realized through radiolabeling of a C-MET receptor antagonist. The radioactive C-MET-targeted affinity micromolecular compound can be used for monitoring the characteristics of biochemical changes of a hepatocyte growth factor receptor, visually displays the distribution and quantity of C-MET and is applicable to specific detection of a plurality of cancers including glioma, lung cancer, prostatic cancer, breast cancer, esophagus cancer, stomach cancer, liver cancer, pancreas cancer, ovarian cancer, rectal cancer and cervical cancer. The radioactive C-MET-targeted affinity micromolecular compound also has certain anticancer activity and has wide clinical application prospect.

The invention relates to a gadolinium oxide targeted magnetic resonance contrast agent, which is polyethylene glycolized Gd2O3 modified by folic acid, expressed as FA-PEG-Gd2O3 and shaped like near-spheres under a transmission electron microscope. A preparation method comprises the following steps: preparing gadolinium oxide nano-particles coated by oleic acid through a high-temperature reduction method, treating gadolinium acetylacetonate in an organic phase to ensure homogeneity and high crystallinity, and performing ligand exchange with silane carboxylic acid to obtain the gadolinium oxide nano-particles with high water solubility. Then, a large number of carboxyl groups of silane are further coupled with NH2-PEG-COOH and NH2-PEG-FA to obtain the gadolinium oxide targeted magnetic resonance contrast agent which is used for early diagnosis of brain glioma.

The invention belongs to the field of biological medicine, relates to a novel brain glioma treatment target, in particular to ribonuclease 4 protein serving as the brain glioma treatment target, further relates to siRNA, shRNA and a neutralizing antibody of the ribonuclease 4 and includes application of the drug prepared from the siRNA, shRNA and the neutralizing antibody and serving as the target to inhibition of growth of brain glioma.The invention discloses application of RNASE4 serving as the drug target to brain glioma inhibition drugs, and the RNASE4 is the ribonuclease 4 and has the amino acid sequence as shown in SEQ ID NO: 1.

The invention belongs to the technical field of medical image processing, and particularly provides a higher level brain glioma survival period prediction method based on a sparse representation framework and a higher level brain glioma survival period prediction system based on the sparse representation framework. Firstly the tumor area in an MRI image is segmented by using an image segmentationmethod based on a convolutional neural network; then the global features of the tumor area are extracted by using the method based on local SIFT feature sparse representation; feature selection is performed by using the model of combining sparse representation and structure preserving for reducing the feature redundancy and enhancing the survival period prediction accuracy, and a few high-stability and high-resolution features are selected to predict the survival period; and finally whether the survival period of the patient is greater than 22 months is predicted by using a multi-feature collaboration sparse representation classification method with combination of the multimodal features. The method has high survival period prediction accuracy, and the whole process is automatically completed by the computer without manual intervention so that the method can be used for postoperative survival period prediction of the clinical higher level brain glioma.

The invention relates to antitumor drugs and discloses anti-glioma drugs based on Venenum Bufonis extract and a preparation method thereof, the drugs being a bufotalin submicron emulsion and a bufotalin nanoparticle preparation, wherein the bufotalin submicron emulsion comprises Venenum Bufonis extract, medium chain triglyceride, a lecithin, poloxamer 188, glycerol, sodium oleate and injection water; the bufotalin nanoparticle preparation comprises Venenum Bufonis extract, glycerol monostearate, medium-chain fatty acid glyceride, oleic acid, a lecithin, poloxamer 188, sodium deoxycholate and injection water. Both the two preparations can combine with endothelial cells in cerebral blood capillaries, enabling the drugs to be transmitted into the brain through membranes or by means of adsorption, medication, endocytosis and transferring, cerebral targeting of the drugs is improved, and further increase of bufotalin in the brain is facilitated, and glioma resistance is achieved by inducing apoptosis and excessive autophagy of cells.

The invention belongs to the fields of biotechnology and medicine, in particular relates to an application of miR-29a as a novel brain glioma marker. The invention first validates that the expressions of the miR-29a in brain glioma tissues and cells are obviously decreased and the miR-29a acting as a tumor inhibiting gene is directly regulated and controlled by p53, and simultaneously first validates that p53 response genes such as MDM4, BCL2L2 and the like are direct targets of the miR-29a. Cytologic experiment proves that the miR-29a can obviously inhibit the propagation and infiltration of brain glioma cells, and animal in-vivo experiment proves that the miR-29a can inhibit the growth of the brain glioma. Besides, the further quantitative analysis of clinical brain glioma specimens of different levels shows that the miR-29a can be used as a brain glioma detection marker.

The invention discloses an application of lncRNA TRALR (long-chain non-coding RNA TRALR). According to the research, lncRNA sequencing shows that lncRNA TRALR has abnormal high expression in a temozolomide-resistant brain glioma cell line, by means of specific interference to expression of lncRNA TRALR, BMI1 can be obviously inhibited and p21 level can be remarkably up-regulated, cell cycle arrestand aging are promoted, and sensitivity of brain glioma to temozolomide is increased. Therefore, a reagent for detecting the expression of lncRNA TRALR can be used for preparing preparations for brain glioma diagnosis and prognosis or sensitivity detection of patients with brain glioma, powerful molecular biology basis is provided for diagnosis, prognosis and chemotherapy sensitivity prediction of the patients with brain glioma, and far-reaching clinical significance and great popularization and application prospect are achieved.

The invention provides tetrazine substituent-containing aromatic isoselenazole compounds as shown in a formula (I) and a formula (II) as well as a preparation method and application of the tetrazine substituent-containing aromatic isoselenazole compounds. The compound disclosed by the invention has the characteristic of targeting TrxR target spots, so that the compound has a good anti-tumor effect on tumors, especially brain glioma. The compound provided by the invention can well inhibit the growth of brain glioma cells in vivo and in vitro as a medicine.

The invention discloses trace gadolinium-doped manganese oxide nanoparticles. Gadolinium-doped manganese oxide nanoparticles are taken as crystal kernels, and the surfaces of the crystal kernels are combined with a silylating reagent; the molar ratio of gadolinium to manganese is 0.01-0.1. The invention further discloses a method for preparing the gadolinium-doped manganese oxide nanoparticles. The gadolinium-doped manganese oxide nanoparticles can be taken as a contrast agent in magnetic resonance imaging, and can be applied to medicament carriers, cell tracing medicaments and gene transfection.

The invention discloses application of a reduction response polymersome nano-drug in preparation of brain tumor treatment drugs. Block copolymers PEG-P(TMC-DTC), PEG-P(LA-DTC), PEG-P(TMC-DTC)-PEI, PEG-P(LA-DTC)-PEI, PEG-P(TMC-DTC)-Sp, PEG-P(LA-DTC)-Sp and targeted polymers thereof are combined in different ratios, and dual-targeted reduction-sensitive reversible crosslinked vesicles of different targeted molecular proportions can be prepared. Through the hydrogen-bond interaction or other electrostatic interaction between great hydrophilic inner cavities of the crosslinked vesicles and / or PEI-spermine and protein drugs or gene drugs, efficient encapsulation of micromolecular chemotherapeutic drugs, the protein drugs and the gene drugs can be achieved. By means of the in-vivo dual-targeteddrug-carrying crosslinked vesicles, more efficient blood brain barrier crossing, higher tissue penetration depth and endocytosis of more glioma cells can be achieved, and the reduction response polymersome nano-drug is very potential in treating brain gliomas and efficient.

The invention discloses a magnetic fluorescent double-model-state probe targeted to brain glioma and a preparation method thereof. Plenty of sulfydryl and carboxyl modified by nanometer particle surfaces are utilized, DTDP can be utilized in the first place to activate the sulfydryl, then mercaptoethylamine is utilized to conduct amination, then connection with carboxyl type fluorescein is conducted, finally RGD is bonded to the carboxyl opposite to the nanometer particle surfaces; or, after EDC / NHS activates the carboxyl on the surfaces of the nanometer particle surfaces, RGD and carboxyl type fluorescein are directly connected to the nanometer particle surfaces. By means of the two methods, a targeting MRI / fluorescent double-model-state probe material can be obtained. The prepared molecular imaging probe achieves MR / fluorescent double-model-state imaging on the cell level and the anima level due to mediation of RGD.

The invention provides grisic quinone A, grisic quinone B, and a preparation method and medical application of the grisic quinone A and the grisic quinone B. Streptomyces griseus P82SMLY separated from marine sediment is provided, and the preservation number is CCTCC NO: M 2015386. Two marine natural products with antiglioma activity, such as the grisic quinone A and the grisic quinone B, are obtained by extracting and classifying a bacterial strain, and the grisic quinone A and the grisic quinone B are new compounds. The grisic quinone A and the grisic quinone B have a feature of obviously inhibiting multiplication of various kinds of glioma cells, can induce apoptosis of the glioma cells obviously, and accordingly can be used for preparing medicines for treating glioma. The chemical structural formula of the grisic quinone A and the grisic quinone B is as shown in the specification.

The invention belongs to the technical field of glioma prognosis markers, and particularly relates to application of BACE2 as a glioma prognosis / treatment marker. According to the invention, the research results prove that high-level BACE2 expression is related to the high-level human brain glioma, the mesenchymal molecule subtype of GBM and the poor prognosis for the first time; furthermore, TGF[beta] 1 stimulates BACE2 expression by means of Smad dependent signal transduction, so as to regulate the activity of TNF-[alpha] induced NF-[kappa] B by means of a PP1 / IKK pathway to promote tumorigenesis in glioma cells. The BACE2 can be used as a novel biomarker and a potential treatment target for treating human brain glioma.

The invention discloses a 5-substituted difluoro piperidine compound capable of penetrating blood brain barrier, wherein the compound has a structural formula represented by a formula (I). According to the present invention, the 5-substituted difluoro piperidine compound, the derivative and the pharmaceutical salt thereof can unexpectedly penetrate blood brain barrier, can have the pharmaceuticalproperties of protein kinase inhibitors, can particularly treat vascular endothelial growth factor receptor 2 or SRC kinase family (FYN)-mediated medical conditions, can further be used for treating or preventing abnormal protein kinase activity related disorders such as cancer, cancer brain metastasis, primary brain cancers such as glioma, malignant glioma, cancer meningeal metastasis, Alzheimer's disease, neurological diseases and the like.

The invention discloses primary cell culture of gliomas, and construction of a PDX model. The PDX model has high fidelity and reserves the histopathological and genetic characteristics and tumor heterogeneity of primary gliomas and is a tumor model with the closest relevance to clinical research at present. The PDX model that simulates the specificity of human gliomas has important transformationsignificance to preclinical evaluation, treatment and prognosis of tumors and is expected to bring new breakthroughs in individualized treatment of patients with gliomas.

The invention discloses a multifunctional targeting vinorebine lipidosome which is composed of vinorebine, lipid materials and functional targeting ligand; the lipidosome is a bi-molecule structure in which a water-solubility cavity is arranged; vinorebine is encapsulated in the water-solubility cavity; the lipid materials are composed of lecithin, cholesterol, polyethylene glycol-DSPE; the functional targeting ligand is composed of modifications on the lipidosome surface and targeting materials in the bi-molecule layer of the lipidosome; the mentioned targeting materials are tetrandrine encapsulated in the bi-molecule layer of the lipidosome; the mentioned modifications are vapreotide-polyethylene glycol 1000 vitamin E succinate and cholesterol-polyethylene glycol-polyethyleneimine. The invention further discloses a preparation method of the multifunctional targeting vinorebine lipidosome, through the method, drugs can be targeted into brain glioma positions after being crossed over blood brain barriers, thereby increasing drug distribution in brain tumor positions and improving chemotherapeutic efficacy.

The invention belongs to the field of biotechnology and relates to an iNGR-modified targeted self-assembly RNAi nano drug delivery system for brain glioma and preparation of the system. A synthetic glutathione-sensitive cationic polymer is utilized to compress spongy loose RNAi nanospheres, and a hydrophilic polymer is utilized for modification to build the ideal-grain-size and reduction-sensitive RNAi nano drug delivery system. The iNGR-modified targeted self-assembly RNAi nano drug delivery system is not only a carrier but also a medicine per se, the in-vivo siRNA delivery efficiency can be remarkably improved, the in-vivo immune reaction and toxic or / and side effects are effectively reduced, and the security of the RNAi nano delivery system is guaranteed. Targeted head-group iNGR tumor penetrating cyclopeptide in the system has favorable tumor angiogenesis targeting effect and tumor tissue penetration capability, and can effectively increase accumulation of the RNAi nano drug delivery system in tumor cells to achieve an excellent brain glioma treatment effect.

The invention relates to application of E3 ubiquitin ligase CHIP in a gliomatosis cerebri disease. In glioma tissues, CHIP is mainly expressed in endochylema of a tumor cell and is localized with labeled protein GFAP (Glial Fibrillary Acidic Protein) of an astroglia, and the expression increases along with the increment of levels; after a CHIP expression amount rises, mRNA (Messenger RNA) and protein expression of a Survivin increase; and after the CHIP expression amount reduces, the mRNA (Messenger RNA) and the protein expression of the Survivin decrease and the protein expression of beta-catenin increases. Through immunohistochemistry, the invention compares the expression conditions of the CHIP in gliomas at different levels and normal gliomatosis cells, clarifies effects and pathological mechanisms of the CHIP in the processes of glioma occurrence, development, proliferation and invasiveness and provides powerful means for the biological target treatment of the glioma in future.

The invention discloses an indocyanine green compound for treating early brain glioma, and a preparation method and an application thereof. The compound has a molecular structure represented by formula (I) described in the specification. The preparation method comprises the following steps: synthesizing a derivative of near-infrared fluorescent molecule indocyanine green (ICG) with a carboxyl group, then connecting Gd-DTPA to the ICG, and finally connecting a targeting cyclic peptide iRGD to obtain the compound. The addition of the iRGD enables the compound to have the capability of targetingvascular endothelial cells and tumor cells at the same time; the size is extremely small, and the efficiency is high; in the early stage of brain glioma, the ICG fragment can efficiently pass throughthe blood brain barrier, target tumor tissue and perform MR / fluorescence bimodal imaging, and the ICG fragment can also realize photothermal and photodynamic therapy.

The invention, belonging to the field of biotechnology, relates to a brain tumor targeting gene delivery composite modified by low density lipoprotein receptor associated protein ligand polypeptide. The brain tumor targeting gene delivery composite has a dual targeting effect of BBB and glioma. Therapeutic genes can express and kill tumor cells in glioma cells, and can release gene product TRAIL protein into the environment outside the cells to combine with tumor cells by the means of cell paracrine after expressing in BCECs and then have a killing effect, thus aiming at the infiltrative growth characteristic of glioma in the brain, the brain tumor targeting gene delivery composite can kill the main glioma and simultaneously effectively inhibit the diffusion of scattered tumor cells.

The invention belongs to the field of biological pharmacy, and relates to an application of P-glycoprotein inhibitors in a drug delivery system modified by DCDX. An amino acid sequence of the DCDX isshown in SEQ NO:1. According to the application of the P-glycoprotein inhibitors in the drug delivery system modified by the DCDX,the application proves that P-gp inhibitors can significantly increasethe amount of intracerebral accumulation and prolong the time of intracerebral accumulation of a liposome drug delivery system modified by the DCDX, and further proves that the P-gp inhibitors can significantly improve the effect of adriamycin liposome modified by the DCDX on brain glioma, therebyproviding a basis for the follow-up combination of the P-gp inhibitors and the liposome drug deliverysystem modified by the DCDX for the treatment of clinical brain diseases, especially brain tumors.

The invention belongs to the field of antineoplastic compounds and relates to a water-soluble derivative of diphenylethene compounds, especially a water-soluble derivative of trans-4-[2-(3,5-dimethoxyphenyl)vinyl]-1,2-benzenediol as shown in the formula I, a preparation method and a usage thereof in the preparation of antitumor drugs. The water-soluble derivative of diphenylethene compounds is prepared through water-soluble reconstruction by taking the compound, trans-4-[2-(3,5- dimethoxyphenyl)vinyl]-1,2-benzenediol, as a parent nucleus. Results of in vitro antineoplastic tests show that the water-soluble derivative of diphenylethene compounds has significant effects in inhibiting brain glioma cells SF188 and U87wt, breast cancer cells MCF-7wt and large cell lung cancer cells H460. The activity of the cells decreases along with the increase of drug concentration. The derivative disclosed by the invention is an effective antitumor agent and further, the derivative can be used for preparing the antitumor drugs.

The invention discloses a novel brain glioma molecular typing method which comprises the following steps: step 1, collecting data, acquiring gene expression profiles and clinical information data from a database, and collecting four independent immunotherapy queues from a public database, including (1) Roh queues: an anti-CTLA4 treatment queue and an anti-PD1 treatment queue; (2) GSE100797: an adoptive T cell treatment queue; and (3) GSE78220: an anti-PD1 treatment queue. the GRI values are obtained through a large amount of data, brain glioma molecules of different patients can be divided, the accuracy of brain glioma molecule division is improved, doctors can be assisted in conducting different types of division on the patients conveniently, scientific treatment is conducted on the patients through different treatment modes, the treatment rehabilitation rate of the patients is increased, and the treatment cost of the patients is reduced. The problem that the traditional brain glioma molecular typing accuracy is low is solved.